STOCK TITAN

Madrigal (MDGL) Form 144: RSU-Vested Shares Proposed for Sale via Morgan Stanley

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Madrigal Pharmaceuticals, Inc. (MDGL) Form 144 notice reports a proposed sale of securities by a person for whose account shares vested as restricted stock units. The filer plans to sell two lots of Common Stock through Morgan Stanley Smith Barney LLC on 08/18/2025: 458 shares (aggregate market value $169,386.72) and 846 shares (aggregate market value $312,884.64). Both lots were acquired on 08/15/2025 by vesting of restricted stock units from the issuer. The filing states there were no sales by the filer in the prior three months and includes the required attestation about material nonpublic information.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Insiders propose a small, post-vesting sale of 1,304 shares executed via a broker on a single date.

The document discloses a proposed sale of 1,304 total shares acquired by RSU vesting on 08/15/2025, to be sold on 08/18/2025 through Morgan Stanley Smith Barney LLC. The filing reports aggregate market values for the two lots as provided and confirms no sales in the prior three months. Based solely on the filing, this is a routine notice required under Rule 144 documenting the insider's intention to sell shares that vested from an equity grant.

TL;DR: Form 144 documents a standard, disclosed insider sale following RSU vesting, with required signature attestations.

The notice identifies the securities as common stock acquired via restricted stock unit grants from the issuer on 08/15/2025. The filer represents they are unaware of undisclosed material adverse information, and no sales were reported in the prior three months. The filing lists the executing broker and planned sale date, meeting procedural disclosure requirements under Rule 144.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What securities does the MDGL Form 144 cover?

The notice covers proposed sales of Common Stock acquired via restricted stock unit vesting.

How many MDGL shares are proposed for sale and when?

A total of 1,304 shares (458 and 846) are proposed to be sold on 08/18/2025.

How and when were the shares acquired according to the filing?

Both lots were acquired on 08/15/2025 through Restricted Stock Unit Grants that vested.

Which broker is handling the proposed sale for MDGL?

The executing broker is Morgan Stanley Smith Barney LLC Executive Financial Services located at 1 New York Plaza, 8th Floor, New York, NY.

Did the filer report any sales of MDGL securities in the prior three months?

The filing states Nothing to Report for securities sold during the past three months.
Madrigal Pharmac

NASDAQ:MDGL

MDGL Rankings

MDGL Latest News

MDGL Latest SEC Filings

MDGL Stock Data

11.16B
20.96M
Biotechnology
Pharmaceutical Preparations
Link
United States
WEST CONSHOHOCKEN